Browse the corpus

Fenofibrate is FDA-approved to treat patients with hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia. It reduces low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B and increases high-density lipoprotein cholesterol in adults. Fenofibrate should be used in conjunction with restricting cholesterol and fat intake and exercise if the response to diet and nonpharmacological interventions alone has been inadequate. Secondary causes of hyperlipidemia should be ruled out before initiating therapy. The therapy should be administered for at least 2 to 3 months before assessing for efficacy. This activity covers the indications, dosing, contraindications, monitoring, and toxicity of fenofibrate so the interprofessional team can optimize its use in therapy. Objectives: Identify the mechanism of action of fenofibrate. Evaluate the potential adverse effects of fenofibrate. Determine the appropriate monitoring of fenofibrate. Explore interprofessional team strategies to enhance care coordination and communication, optimizing the use of fenofibrate and improving patient outcomes. Access free multiple choice questions on this topic.

The most common toxicity associated with fenofibrate is myopathy when given with statin medicines concurrently. If rhabdomyolysis is excluded and other muscle-related diseases are suspected, the statin-associated muscle symptoms clinical index (SAMS-CI) should be evaluated to determine if muscle symptoms are due to statin therapy. Discontinuing fenofibrate, administering vitamin D replacement (for low vitamin D levels), and switching the medication are all possible options depending on the cause of myopathy.[12] There is no specific treatment available for the overdose of fenofibrate. General supportive care is recommended for the patient. The vital signs and clinical status should be monitored if an overdose occurs. If needed, the elimination of unabsorbed drugs should be attained by emesis or gastric lavage. Monitoring of clear airway is also recommended. As fenofibric acid has high plasma protein binding, hemodialysis for eliminating drugs should not be considered.

An interprofessional healthcare team including clinicians, nurses, and pharmacists is optimal for managing treatment with fenofibrate. Medical professionals should be aware of the signs and symptoms accompanying fenofibrate toxicity. The involvement of other specialized professionals, including a nephrologist or toxicologist, should be considered to ensure an optimal patient result. Clinicians must counsel patients regarding any symptoms associated with liver damage (weakness, weight change, abdominal pain, jaundice). Interprofessional care coordination with open communication among team members results in the best possible outcomes with the fewest adverse events. Pharmacists should actively monitor drug interactions before dispensing medication and notify the prescriber or nurse of potential issues. In addition, the medical care provider should advise the patient on the importance of reading the labels of the medication to avoid drug misuse or overdose. An interactive team dynamic for fenofibrate therapy is essential in managing adverse effects and providing successful patient care for optimal therapeutic outcomes.